HIV isolate from Kenya provides clues for vaccine design

January 2, 2008

Two simple changes in its outer envelope protein could render the AIDS virus vulnerable to attack by the immune system, according to research from Kenya and the Fred Hutchinson Cancer Research Center published in PLoS Medicine.

The results could provide important clues for designing an effective AIDS vaccine, which is badly needed to decrease the number of new HIV infections, now estimated at about 2.5 million per year worldwide.

Although most people infected with HIV produce antibodies against the virus within several weeks following infection, these antibodies rarely prevent the infection from progressing to symptomatic AIDS.

While studying a group of women at risk of HIV in Mombasa, Julie Overbaugh and colleagues noticed that one woman carried an AIDS virus that was easily inactivated by antibodies. They initially described this case in 2007 in the Journal AIDS.

Analyzing this woman’s virus, they found that it contains mutations in four amino acids in the envelope protein, two of which, when introduced into unrelated strains of HIV in the laboratory, conferred sensitivity to inactivation by a number of antibodies produced in people infected with HIV.

The researchers propose that these mutations cause a change in the overall structure of the envelope protein that results in exposure to the immune system of regions that are normally hidden. If further research confirms this idea, vaccines containing envelope proteins that include these mutations might be able to stimulate an antibody response that would protect against infection with HIV.


Source: Public Library of Science

Explore further: New research shows promise for immunotherapy as HIV treatment

Related Stories

New research shows promise for immunotherapy as HIV treatment

November 9, 2016

Immunotherapy has revolutionized treatment options in oncology, neurology, and many infectious diseases and now there is fresh hope that the same method could be used to treat or functionally cure HIV, according to two related ...

Antibody suppresses HIV in infected individuals

November 10, 2016

The administration of VRC01, a potent and broadly neutralizing HIV-specific antibody, is safe, is well-tolerated, generated high plasma concentrations and modestly delayed the return of HIV viral rebound in HIV-1 infected ...

Recommended for you

S.Africa launches major new trial of AIDS vaccine

November 29, 2016

South Africa on Wednesday launched a major clinical trial of an experimental vaccine against the AIDS virus, which scientists hope could be the "final nail in the coffin" for the disease.

HIV survives in our chromosomal DNA

November 17, 2016

It has been said that HIV cannot be cured since the virus propagates in places beyond the reach of antiviral agents. New research from Karolinska Institutet suggests, however, that this view is incorrect.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.